United Therapeutics Corporation Reports First Quarter 2026 Financial Results
United Therapeutics reported Q1 2026 revenue of $781.5 million, down 2% year-over-year, with net income decreasing 15% to $274.9 million. The company announced a $2.0 billion share repurchase authorization, with $1.5 billion already executed via ASR agreements, leaving $500 million available.
Key figures
- Eps
- 5.82
- Revenue
- 781500000
- Guidance
- Committed to return to sequential quarterly revenue growth across commercial portfolio in the near term
- Revenue Yoy
- -2%
- Net income
- 274900000
- Operating income
- 325800000
- Tyvaso dpi revenue
- 330300000
- Nebulized tyvaso revenue
- 127200000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.